Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: Standard versus long nocturnal hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 4, 2013, Pages 407-411

  Knap, Bojan ^a   Večerić Haler, Željka ^a   Benedik, Miha ^a   Buturović Ponikvar, Jadranka ^a   Ponikvar, Rafael ^a   Bren, Andrej F ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Fibroblast growth factor 23; Hemodialysis; Intact parathyroid hormone; Left ventricular hypertrophy; Nocturnal hemodialysis

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE;

ADULT; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAINTENANCE THERAPY; MALE; NOCTURNAL HEMODIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; STANDARD; TREATMENT DURATION; VASCULITIS;

FIBROBLAST GROWTH FACTOR-23; HEMODIALYSIS; INTACT PARATHYROID HORMONE; LEFT VENTRICULAR HYPERTROPHY; NOCTURNAL HEMODIALYSIS;

ADULT; AGED; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 84881484802     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12087     Document Type: Article

References (21)

1. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001;12:1079-1084.
2. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012;21:369-375.
3. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-1647.
4. Gutierrez OM, Januzzi JL, Isakova T etal. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552.
5. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82:737-747.
6. Shimada T, Hasegawa H, Yamazaki Y etal. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-435.
7. Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol 2010;23:653-657.
8. Juppner H. Phosphate and FGF-23. Kidney Int 2011;79(Suppl 121):24-27.
9. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int 2002;62(Suppl 82):73-80.
10. Toussaint ND, Pedagogos E, Tan SJ etal. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. J Nephrol (Carlton) 2012;17:433-444.
11. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19:1092-1105.
12. Kestenbaum B, Sampson JN, Rudser KD etal. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
13. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol 2012;21:372-381.
14. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;61:2235-2239.
15. Wald R, Yan AT, Perl J etal. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrol 2012;13:3. doi: 10.1186/1471-2369-13-3
16. Isakova T. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2012;21:334-340.
17. Larsson T, Nisbeth U, Ljunggren O, Jupner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2279.
18. Faul C, Amaral AP, Oskouei B etal. FGF 23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
19. Shalhoub V, Shatzen EM, Ward SC etal. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;22:2543-2553.
20. Moe OW. Fibroblast growth factor 23: friend or foe in uremia? J Clin Invest 2012;122:2354-2356.
21. Nessim SJ, Jassal SV, Fung SV, Chan CT. Conversion from conventional to nocturnal hemodialysis improves vitamin D levels. Kidney Int 2007;71:1172-1176.